These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 16771724

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Population based study of hormonal therapy and survival in men with metastatic prostate cancer.
    Lu-Yao G, Moore DF, Oleynick JU, DiPaola RS, Yao SL.
    J Urol; 2007 Feb; 177(2):535-9. PubMed ID: 17222628
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T, Kinjo M, Nutahara K, Higashihara E.
    Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
    Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M, Yamanaka H, Japan Study Group of Prostate Cancer (J-CaP).
    Jpn J Clin Oncol; 2007 Oct; 37(10):775-81. PubMed ID: 17965423
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
    Azuma H, Sakamoto T, Kiyama S, Ubai T, Kotake Y, Inamoto T, Takahara K, Nishimura Y, Segawa N, Katsuoka Y.
    Am J Clin Oncol; 2008 Apr; 31(2):188-94. PubMed ID: 18391605
    [Abstract] [Full Text] [Related]

  • 16. [Combined hormone and chemotherapy for the patients with advanced prostate cancer].
    Uekado Y, Hirano A, Inagaki T, Hiroi A, Watanabe T.
    Gan To Kagaku Ryoho; 1995 Jul; 22(8):1041-5. PubMed ID: 7611755
    [Abstract] [Full Text] [Related]

  • 17. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C.
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Failure to achieve a PSA level <or=1 ng/mL after neoadjuvant LHRHa therapy predicts for lower biochemical control rate and overall survival in localized prostate cancer treated with radiotherapy.
    Mitchell DM, McAleese J, Park RM, Stewart DP, Stranex S, Eakin RL, Houston RF, O'Sullivan JM.
    Int J Radiat Oncol Biol Phys; 2007 Dec 01; 69(5):1467-71. PubMed ID: 17689886
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.